MIRA Pharmaceuticals Consensus Price Target Increased by 16.67% to $3.57

The average one-year price target for MIRA Pharmaceuticals (NASDAQCM:MIRA) (DB:K6S) has been revised to $3.57 / share. This is an increase of 16.67% from the prior estimate of $3.06 dated January 11, 2026. These figures represent aggregate analyst targets collected by Fintel, rather than a recommendation orinvestment advicefrom Fintel itself. The price target is an average of many targets provided by analysts. The latest targets range from a low of $3.54 to a high of $3.68 / share. The average price target represents an increase of 388.97% from the latest reported closing price of $0.73 / share as of October 2, 2026. The median target increased to $3.57 from $3.06, representing an absolute median change of $0.51. The target range widened, with the current target range width at $0.14 compared to the prior width of $0.12, a target range width change of +16.67%. Looking at the target history, the mean target was $3.57 on October 3, 2026, and was $3.06 on January 14, 2026, December 21, 2025, and December 6, 2025. The observed twelve-month high mean target is $3.57, recorded on October 3, 2026, while the observed twelve-month low mean target is $3.06, recorded on January 14, 2026. As context for the company's market performance, the stock price decreased 18.88% over one week, from a baseline close of $0.90 on September 25, 2026, to its closing price of $0.73 on October 2, 2026. Over a one-month period, the price decreased 14.06% from a baseline close of $0.85 on September 2, 2026. In its latest earnings report on August 12, 2026, MIRA Pharmaceuticals reported an actual EPS of -0.03 on actual revenue of $0.00. MIRA Pharmaceuticals is a US-based biotechnology company focused on developing innovative therapies for serious diseases, including oncology and immunology. On September 17, 2026, Maxim Group initiated coverage on the company with a Buy grade. The current analyst recommendation profile as of May 1, 2026, shows a total of 7 recommendations, with 85.7% positive, 14.3% hold, and 0.0% negative. This recommendation distribution is unchanged from the prior period as of April 1, 2026. Within the broader Biotechnology sub-industry, 24 companies are covered. Among these, 7 experienced target raises, 6 saw targets lowered, and 11 remained unchanged, resulting in a sub-industry median revision of 0.00% and a median implied change of +79.31%. Among its peers in the biotechnology sector, target revisions and implied changes varied. Agenus and Atossa Therapeutics saw positive target revisions, while Arvinas remained unchanged. Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits. Click to Learn More This story originally appeared on Fintel.

MIRA Pharmaceuticals Consensus Price Target Increased by 16.67% to $3.57

Інші новини компанії